Coeptis Therapeutics jumps on research tie-up with University of Pittsburgh

Z Squared (Delaware)

31/01/2023 15:00

** Shares of cancer therapy developer Coeptis Therapeutics
Holdings Inc  COEP.O  jump 13.3% to $1.87  
    ** Co says it has entered into a sponsor research agreement
with University of Pittsburgh to develop a type of cell therapy
to treat various types of cancer
    ** University of Pittsburgh will conduct pre-clinical study
on co's cell therapy candidate, SNAP-CAR, for the potential
treatment of ovarian cancer which overexpresses a protein called
human epidermal growth factor receptor 2       
    ** SNAP-CAR belongs to a class of drugs called chimeric
antigen receptor T cell (CAR T) therapy
    ** SNAP-CAR is designed to be a 'universal' CAR T cell
therapy platform that can be adapted to different cancer
indications -COEP 
    ** CAR T uses a patient's own immune response-generating T
cells, which are then genetically modified to attack cancer
cells 
    ** Including session moves, stock has fallen ~81.4% in the
past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))